Immunologic responses to anti-PD-1 therapy in melanoma patients occur rapidly with pharmacodynamic T cell responses detectable in blood by 3 weeks. It is unclear, however, whether these early blood-based observations translate to the tumor microenvironment. We conducted a study of neoadjuvant/adjuvant anti-PD-1 therapy in stage III/IV melanoma. We hypothesized that immune reinvigoration in the tumor would be detectable at 3 weeks and that this response would correlate with disease-free survival. We identified a rapid and potent anti-tumor response, with 8 of 27 patients experiencing a complete or major pathological response after a single dose of anti-PD-1, all of whom remain disease free. These rapid pathologic and clinical responses were associated with accumulation of exhausted CD8 T cells in the tumor at 3 weeks, with reinvigoration in the blood observed as early as 1 week. Transcriptional analysis demonstrated a pretreatment immune signature (neoadjuvant response signature) that was associated with clinical benefit. In contrast, patients with disease recurrence displayed mechanisms of resistance including immune suppression, mutational escape, and/or tumor evolution. Neoadjuvant anti-PD-1 treatment is effective in high-risk resectable stage III/IV melanoma. Pathological response and immunological analyses after a single neoadjuvant dose can be used to predict clinical outcome and to dissect underlying mechanisms in checkpoint blockade.
Immunologic responses to anti-PD-1 therapy in melanoma patients occur rapidly with pharmacodynamic T cell responses detectable in blood by 3 weeks. It is unclear, however, whether these early blood-based observations translate to the tumor microenvironment. We conducted a study of neoadjuvant/adjuvant anti-PD-1 therapy in stage III/IV melanoma. We hypothesized that immune reinvigoration in the tumor would be detectable at 3 weeks and that this response would correlate with disease-free survival. We identified a rapid and potent anti-tumor response, with 8 of 27 patients experiencing a complete or major pathological response after a single dose of anti-PD-1, all of whom remain disease free. These rapid pathologic and clinical responses were associated with accumulation of exhausted CD8 T cells in the tumor at 3 weeks, with reinvigoration in the blood observed as early as 1 week. Transcriptional analysis demonstrated a pretreatment immune signature (neoadjuvant response signature) that was associated with clinical benefit. In contrast, patients with disease recurrence displayed mechanisms of resistance including immune suppression, mutational escape, and/or tumor evolution. Neoadjuvant anti-PD-1 treatment is effective in high-risk resectable stage III/IV melanoma. Pathological response and immunological analyses after a single neoadjuvant dose can be used to predict clinical outcome and to dissect underlying mechanisms in checkpoint blockade.
Clinical responses to anti-PD-1 therapies can occur rapidly 1, 2 . A pharmacodynamic response including reinvigoration of exhaustedphenotype CD8 T cells (T EX ) can be detected in blood of cancer patients after a single dose 3, 4 . However, the precise type(s) of T cells in the tumor that respond to anti-PD-1 remains poorly understood. Moreover, whereas early immunological responses to checkpoint blockade are observed at 3 weeks in blood, the kinetics of immune reinvigoration in the tumor and the relationship to pathological response and clinical outcomes are unclear.
We conducted a neoadjuvant/adjuvant anti-PD-1 clinical trial in stage III/IV resectable melanoma. This approach provided early on-treatment tumor tissue at resection and insights into the mechanisms of PD-1 blockade. Our study demonstrated the clinical feasibility of neoadjuvant/adjuvant anti-PD-1 therapy in melanoma, and identified a rapid pathological and immunologic response in tumors. Complete pathological responses could be identified by 3 weeks and correlated with disease-free survival (DFS). Data from early on-treatment resected tumor indicate that T EX , but not bystander cells, are a major responding cell type. Studies in an additional cohort identified reinvigoration of T EX as early as day 7 after the first dose of anti-PD-1. Finally, in patients who developed disease recurrence, potential mechanisms of resistance were identified.
Results
A pharmacodynamic immune response can be detected in blood 3 weeks after initiation of PD-1 blockade 3, 4 . To understand the A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma 1 
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We assessed the pathologic response after 1 dose of pembrolizumab in the resection specimens of 27 patients available at time of data cut-off. Resected tumor had features of completely viable, mixed viable and necrotic, or completely necrotic tumor on gross examination ( Fig. 1b ). On histologic assessment, 8 of 27 patients (29.6%; 95% confidence interval, 13.8-50.2%) had a complete (no residual tumor identified; n = 5) or major (10% or less viable tumor cells; n = 3) pathologic response 5, 6 (Fig. 1c ). The median duration of follow-up for DFS was 25 months; median DFS has not been reached. The 1-year DFS rate ± s.e.m. was 63% ± 9% ( Fig. 1d ).
Approximately 30% of patients had a complete or major pathologic response after 1 dose of pembrolizumab, consistent with a recent neoadjuvant anti-PD-1 clinical trial in melanoma that observed a pathologic complete response (pCR) of 25% after 4 doses of nivolumab 7 . In 20 patients with paired pre-and post-treatment tumor samples, the percentage of viable tumor significantly decreased after treatment ( Fig. 1e ). All patients with complete or major pathologic responses remain disease free ( Fig. 1f ); viable tumor ≤10% at resection was associated with a low risk of recurrence independent of stage ( Supplementary Table 3 ). Lactate dehydrogenase, BRAF status, and tumor burden (unidimensional tumor diameter) were not associated with recurrence (Supplementary Table 3 ). In 20 patients with paired samples, a single dose of pembrolizumab significantly increased the fraction of patients with brisk tumor infiltrating lymphocytes (TILs) ( Supplementary Table 4 and Fig. 1g ) which was also associated with complete or major pathologic response (Supplementary Table 5 and Extended Data Fig. 1 ) and significantly improved DFS ( Supplementary Table 3 and Fig. 1h ).
We examined a subset of 6 patients that had early imaging at 3 weeks (trial no. UPCC11615). 18 F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) scans were performed at baseline and before surgical resection; images were analyzed per RECIST 1.1. Consistent with the pathological responses, radiographic responses were observed after one dose of anti-PD-1. In 3 patients, we observed a ≥20% decrease in tumor diameter and these patients remained recurrence free ( Fig. 2a ). In contrast, the 3 patients without evidence of tumor shrinkage at 3 weeks had recurrences. Changes in tumor size at 3 weeks correlated with the percentage of viable tumor observed histologically (Fig. 2b,c ). However, changes in FDG avidity were not associated with response (data not shown). The percentage of viable tumor at 3 weeks was correlated with a change in tumor dimensions by imaging and recurrence status which were both inversely correlated with TIL infiltration (Fig. 2d ,e and Supplementary Table 5 ).
Given the rapid pathological effects of anti-PD-1, we hypothesized that the reinvigoration of anti-tumor immune responses might occur before 3 weeks. Indeed, there is anecdotal evidence of expansion of CD39 + T EX 9 days after anti-PD-1 8 . We conducted an additional trial of anti-PD-1 (UPCC02616) with blood collected at day 7 after initiation of therapy. We observed robust increases in Ki67 + CD8 T cells at day 7; the responding cells were PD-1 + and enriched for cells that coexpressed PD-1 and CTLA-4 ( Fig. 2f,g ). This response peaked at day 7 and then declined. Analysis of the Ki67 + cells at day 7 and week 3 showed similarity in expression of markers of differentiation state (CD45RA, CD27), inhibitory receptors (PD-1, CTLA-4), and other markers of T cell exhaustion (CD39) ( Fig. 2h ,i), indicating similar qualitative responses at day 7 and 3 weeks. Ki67 + cells pretreatment also had similar phenotype, suggesting that PD-1 blockade reinvigorates a pre-existing pool of T EX (Fig. 2i ). The robust response of T EX -like CD8 T cells to anti-PD-1 as early as 7 days post-treatment is consistent with the robust tumor eradication in many patients by 3 weeks.
To further investigate the nature of the rapid intratumoral response to anti-PD-1, we compared peripheral blood mononuclear cells (PBMCs) to TILs at week 3. Increased proliferation of CD8, CD4, and FoxP3 + regulatory T cells (Tregs) was detected in the blood after anti-PD-1 (Extended Data Fig. 2a ), as described 3 . In the tumor, CD8 T cell proliferation increased (Extended Data Fig. 2b ) and, as expected 9,10 , pembrolizumab treatment increased CD8 T cell infiltration (Fig. 3a) . The majority of CD8 T cells in the tumor were CD45RA lo CD27 hi . PD-1 was coexpressed with Tim-3, CTLA-4, LAG3, TIGIT, and CD39 (ref. 11 ), and many of these TIL CD8 T cells expressed high Eomes, but low T-bet ( Fig. 3b,c) , consistent with the phenotype of T EX 12, 13 . In addition, the majority of CD8 T cells in the tumor were bound by pembrolizumab ( Fig. 3d) . At 3 weeks there was a robust increase in Ki67 in PD-1 + and PD-1 + CTLA-4 + CD8 T cells in the blood. Although there was an increase in Ki67 in PD-1 + CD8 T cells in the tumor, the PD-1 + CTLA-4 + subset lacked a consistent increase in Ki67, whereas the proportion of PD-1 + CTLA-4 + CD8 T cells in the tumor increased following treatment ( Fig. 3e ). This finding suggested that: (1) immune reinvigoration in the tumor may be early and transient, while systemic reinvigoration may be sustained, and/or (2) T cells may be reinvigorated in the periphery before trafficking to the tumor.
We observed a high frequency of PD-1 + CD39 + CD8 T cells in the TILs pretreatment ( Fig. 3b ), consistent with tumor-reactive T cells 8 . To examine tumor specificity in more detail, we examined gp100 and cytomegalovirus (CMV)-specific CD8 T cells using HLA/peptide tetramers pre-and post-treatment in two patients. There were no consistent changes for these populations in the blood following treatment. However, in both patients, gp100-specific CD8 T cells were present at higher frequencies in the tumor than blood pretreatment and these cells increased in frequency after anti-PD-1 ( Fig. 3f ). Conversely, CMV-specific CD8 T cells in the tumor did not expand after treatment. At week 3, gp100-specific CD8 T cells in the tumor were CD45RA lo CD27 hi ; expressed high PD-1, Tim-3, and CTLA-4; and most were Eomes hi T-bet lo (Fig. 3g ,h). Compared with blood, the gp100-specific CD8 T cells in the tumor had similar PD-1, more Tim-3 and CTLA-4, but less Ki67. In contrast, CMV-specific CD8 T cells in the blood were CD45RA hi CD27 lo , coexpressed Eomes and T-bet, and had lower inhibitor receptors ( Fig. 3h ). Thus, melanomaspecific CD8 T cells in the blood and tumor of a subset of patients had a phenotype consistent with T EX in the tumor and increased numerically after anti-PD-1.
We next studied the cellular determinants of anti-PD-1 response versus resistance in this cohort. Anti-PD-1 increased CD8 T cells in the tumor (Fig. 3a) , but also increased PD-L1 and Tregs (Extended Data Fig. 3a and Fig. 4a ). Proliferation of CD8 T cells in the tumor also correlated with Treg proliferation (Extended Data Fig. 3b ), suggesting rapid upregulation of immunoregulatory feedback mechanisms. Random forest analysis in the tumor post-treatment revealed Eomes expression and Treg proliferation as strong correlates of recurrence-free survival (Extended Data Fig. 3c ). A high percentage of Eomes hi T-bet lo T EX was associated with clinical benefit and Treg proliferation was associated with recurrence and poor DFS (Extended Data Fig. 3d and Fig. 4b ). Treg proliferation was inversely correlated with the frequency of Eomes hi T-bet lo T EX (Extended Data Fig. 3e ). Random forest analysis of pretreatment immune parameters identified baseline Ki67 expression by non-naïve CD8 T cells as associated with clinical benefit ( Fig. 4c and Extended Data Fig. 3f -h), suggesting that pre-existing CD8 T cell responses drive clinical responses to anti-PD-1 (refs. 10, 14 ) .
NanoString analysis of post-treatment tumor revealed a distinct signature of T cell activation compared with pretreatment including CD8A, CD8B, GZMA, GZMK, ZAP70, LAT, and CD69 (Extended Data Fig. 4a ). Pretreatment, we also identified a strong neoadjuvant response signature (NRS) including genes involved in T cell activation, adaptive immune response, and T cell migration ( Fig. 4d -f) that correlated with post-treatment TIL responses and recurrence-free survival. This finding is consistent with T cell-inflamed Letters | FOCUS Nature MediciNe tumors described in stage IV disease 10, [15] [16] [17] . Indeed, an 18-gene IFNγ T cell-inflamed signature, GEP18, predictive of clinical response to pembrolizumab in unresectable locally advanced and metastatic cancers 15, 18 , was also associated with clinical response in our largely stage III setting (Extended Data Fig. 4b ). The NRS strongly enriched for the transcriptional signatures 19 from either effector (T EFF ) or memory (T MEM ) CD8 T cells compared with naïve CD8 T cells (T NAIVE ) and also enriched strongly for the signature of T EX from mice 19 (Extended Data Fig. 4c ). Moreover, there was a stronger enrichment of the T EX signature when compared directly with T EFF (Fig. 4g ), suggesting the importance of preexisting T EX . In addition, high expression of genes involved in angiogenesis and B cell receptor pathways was associated with clinical benefit (Extended Data Fig. 4d,e ), implicating possible 
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T cell-independent mechanisms of anti-PD-1 response and changes in the tumor microenvironment. Ten patients have recurred thus far, seven of whom developed distant metastatic disease, two of whom have died (Extended Data Fig. 5a,b ). To study mechanisms of resistance, we collected recurrence tumor samples from three patients and compared them with the resection samples ( Fig. 4h-k) . There was no significant difference in the number of predicted total, or high-quality, neoantigens likely to be recognized by T cell receptors (TCRs) (Extended Data Fig. 5c,d) . Patients 01615-06 and 01615-13, however, displayed few CD8 T cells by immunofluorescence, low Ki67, and low percentages of PD-1 + or PD-1 + CTLA-4 + CD8 T cells in the resection tumor and at progression (Fig. 4i,j) . Furthermore, there was a prominent increase in CD163 + myeloid cells with a concomitant decrease in CD3 + cells in both patients (Fig. 4i ). Although patient 01615-13 had evidence of T cell activation on progression based on NanoString, there was a concomitant signature of myeloid chemotaxis and activation, including CD14, CCL8, CXCL14, CLEC5A, and CSF1R (Fig. 4h) . Moreover, analysis of whole exome sequencing data revealed a deleterious single-nucleotide variant (SNV) at the TP53 locus (encoding p53) that was heterozygous at resection (allele frequency of 0.55), but homozygous at recurrence (allele frequency of 0.84; Fig. 4k ). P53, a tumor suppressor, may also play a role in immunogenic cell death, CD8 T cell responses, and suppressive myeloid subsets such at MDSCs (myeloid-derived suppresor cells) 20 . Thus, p53 loss may lead to a more aggressive tumor at recurrence and decreased anti-tumor immunity, including increased suppressive myeloid cells. In patient 01615-06, there was little transcriptomic change between resection and recurrence (Fig. 4h) ; the underlying drivers of progression are unknown. Finally, patient 01615-03 had prominent T cell infiltration post-treatment including many PD-1 + CTLA-4 + cells with a high percentage of Ki67 + cells (Fig. 4i,j) . This population of cells phenotypically resembled T EX that are associated with positive clinical responses in other settings 3, 4, 21 , suggesting a disconnect between this reinvigorated T EX -like population and the lack of tumor control. Whole exome sequencing, however, revealed loss of heterozygosity in B2M on recurrence, with an increase in mutant allele frequency from 0.52 to 0.91 ( Fig. 4k ), providing a possible explanation for tumor progression despite a vigorous CD8 T cell response to anti-PD-1. Thus, although mechanisms of adaptive resistance have been described that involve mutation, including loss of B2M [22] [23] [24] , suppressive myeloid cells 25 , and 'cold tumor' microenvironments 17, 26, 27 , these data highlight the importance of a neoadjuvant approach to potentially identify these mechanisms early on during treatment.
Discussion
Despite the clinical success of checkpoint blockade, we still understand relatively little about the precise mechanism(s) of response or resistance to these treatments. A neoadjuvant approach with anti-PD-1 therapy allowed us to address this question and was feasible and effective in stages IIIB/C and IV melanoma with 63% DFS and 93% overall survival at 2 years. There are several major findings. First, we observed a rapid immune response after PD-1 blockade with T cell reinvigoration peaking 7 days post treatment initiation and complete or major pathologic response in 30% of patients within 3 weeks. Notably, these patients with early complete or major pathological tumor response have 100% DFS at 24 months. In contrast, patients without robust pathological responses at surgery had a poor prognosis with greater than 50% risk of recurrence despite adjuvant therapy. A neoadjuvant approach might allow for early identification of high-risk patients and a change to more effective adjuvant therapy. Second, the data from TILs pre-and posttreatment support a role for CD8 T cells with characteristics of T EX . Finally, these studies provide evidence for mechanisms of response and adaptive resistance including immune failure, immune regulation, and immune escape.
Many patients displayed rapid (3 weeks) complete or nearly complete pathologic responses. These data support the notion that anti-PD-1 revitalizes an already-existing T cell response. In support of this hypothesis are the observations that baseline proliferation of CD8 T cells was associated with clinical benefit and that the immunologic pharmacodynamic response to PD-1 blockade peaked at day 7 after treatment initiation. Although new T cell priming cannot be excluded, this rapidity and robustness favors a model where previously primed CD8 T cells become exhausted and then, on PD-1 blockade, get rapidly reinvigorated. These immune response data are consistent with the rapid anti-tumor responses observed, but also suggest that preventing or avoiding early concomitant immunoregulatory (for example, Treg) and/or later acquired resistance may require combination immunotherapies delivered at times that synergize with this early response to anti-PD-1 therapy.
An obvious question relates to the specificity of the CD8 T cells responding to PD-1 blockade. Previous work has shown that the T EX -phenotype cells in the blood responding to PD-1 blockade were enriched for TCRs also found in TILs 3 . Although it is possible that some of these cells are bystander cells that can be found in blood and tumor, our current studies suggest that CMV-specific CD8 T cells are not likely to respond to anti-PD-1, whereas tumor-specific CD8 T cells targeting gp100 do respond. Moreover, recent work indicates that the PD-1 + CD39 + subset of T EX is enriched for tumor-specific T cells compared with the CD39-subset 8 and we find strong enrichment for the CD39 + subset among the cells responding to PD-1 blockade in this cohort. It will be important to extend these types of studies to larger cohorts with detectable shared or neoantigen-specific CD8 T cell populations. However, based on these previous studies, the cells responding to PD-1 blockade in the cohorts analyzed here are likely to be enriched for tumor-specific CD8 T cell populations.
We
identified an association between accumulation of T EX -phenotype (Eomes hi T-bet lo ) CD8 T cells and clinical benefit.
Minimal changes in Ki67 at 3 weeks contrasted with an increased frequency of T EX -like cells in the tumor after anti-PD-1. These Kaplan-Maier estimate of DFS stratified according to CART-defined cut-off for Treg Ki67 (right, Ki67 < 12.4, n = 9; Ki67 ≥ 12.4, n = 13). P value calculated using logrank test. c. Kaplan-Maier estimate of DFS stratified according to CART-defined cut-off for non-naïve CD8 Ki67 at baseline (Ki67 > 5.5, n = 13; Ki67 ≥ 12.4, n = 8). P value calculated using log-rank test. d. Heatmap of 69 differentially expressed genes (NRS) at the pretreatment time point between patients with no recurrence (n = 9 patients) and recurrence (n = 5 patients). Differentially expressed genes identified using FDR cut-off of P = 0.05. e, Pathways identified using gene ontology (GO) analysis. f, Volcano plot of differentially expressed genes. g, GSEA of the NRS; genes that were enriched in T EX versus T EFF cell signatures from Doering et al. 19 . h, NanoString gene expression data showing log 2 fold change between progression versus post samples (x axis), and expression at progression (y axis). i, Lymphocyte subsets at post and progression time points by immunohistochemistry (IHC) and IF. j, Flow plots of selected markers at post and progression time points for three individual patients. k, Integrative Genomics Viewer images corresponding to B2M and TP53 mutations at post and progression time points. Adj, adjusted; CART, classification and regression tree analysis; Eff, effector; Ex, exhausted; FC, fold change; FDR, false discovery rate; N, no; NES, normalized enrichment score; Y, yes. 
observations suggest that either reinvigoration in the tumor occurs before week 3, and/or that T EX are reinvigorated peripherally and migrate to the tumor. Indeed, our data demonstrate a peak of T EX reinvigoration in the blood by day 7 and data in mice suggest that immune activity in the tumor occurs early and transiently, whereas a systemic immune response may persist longer 28 . Ki67 + Tregs were also observed in the tumor and correlated with Ki67 + CD8 T cells at week 3. Moreover, proliferation of Tregs was associated with poor DFS. PD-1 blockade may therefore reinvigorate T EX in the tumor but also activate Tregs; the relationship between these changes may be an important feature influencing clinical outcome and an opportunity for Treg-modulating drugs. Analysis of pretreatment tumor also revealed Ki67 expression by non-naïve CD8 T cells as a potential pretreatment biomarker of response. This observation is consistent 
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Nature MediciNe with published data in stage IV melanoma where pre-existing CD8 T cells in the tumor are associated with clinical benefit following PD-1 blockade 10 . Our data demonstrate that this pre-existing CD8 T cell immune response is initiated earlier in cancer development (stage III disease). Consistent with this notion, NanoString data demonstrated a distinct inflamed signature before therapy. These observations support the idea that, even in localized disease, the tumor microenvironment is already primed for response or non-response to checkpoint blockade. In patients who recurred, distinct genomic and cellular resistance factors were identified, including B2M and P53 loss of heterozygosity, as well as increased myeloid cell accumulation. Future neoadjuvant studies will allow further study of mechanisms of resistance that may help tailor therapies and/or clinical trials in patients.
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Methods Study design and patient population. This phase 1b clinical trial (NCT02434354) was a single institution investigator-initiated study sponsored by the University of Pennsylvania. The protocol and its amendments were approved by the Institutional Review Board at the University of Pennsylvania, and all patients provided written informed consent. Patients were eligible for enrollment if they were 18 years of age or older, had an Eastern Cooperative Group performance status of 0 or 1, had adequate organ function according to protocol criteria, and had measurable resectable clinical stage III or resectable stage IV melanoma. Patients had to have an adequate tumor size, in the opinion of the surgical oncologist and study team, to allow for collection of biopsy tissue equivalent to at least two to four core biopsies for the pretreatment biopsy, with an expectation that an equal or greater amount of tissue would remain after biopsy. Patients could not have received previous ipilimumab or other immune therapies. Previous BRAF-directed therapies were permitted. Patients with uveal or mucosal melanoma were not eligible, nor were patients on systemic steroids or immunosuppression, patients who had received radiation to the resectable tumor, or patients with active brain metastasis.
Treatment and assessment. After obtaining informed consent, all patients underwent a baseline pretreatment biopsy, which consisted of the equivalent amount of tissue of at least two to four core biopsies. Patients then received a single flat dose of pembrolizumab 200 mg intravenously, followed by complete resection 3 weeks later. Patients also provided paired blood samples at the pretreatment and post-treatment time points. After resection and on surgical recovery, patients continued to receive adjuvant pembrolizumab every 3 weeks for up to 1 yr, or until the time of recurrence or any unacceptable treatment-related toxicity (Fig. 1a ).
Both the biopsies and the resection specimens were processed in the Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, and immediately snap or formalin fixed and paraffin embedded, with a portion of unfixed tissue allocated for extraction of TILs for translational studies. Gross photos were taken of resection specimens. Patients were assessed for pathologic response at the 3-week resection time point, with the resection tumor assessed for percentage of viable tumor by a melanoma pathologist. Complete pathologic response was defined as the absence of viable tumor based on hematoxylin and eosin (H&E) staining. A major pathologic response was defined as less than 10% of viable tumor. Pre-and post-treatment tumors were also assessed for TIL infiltration and scored as either brisk (diffuse lymphocytes throughout the tumor), non-brisk (only foci of lymphocytes), or absent 29 . Imaging (PET-CT or computed tomography of the chest, abdomen, and pelvis) was performed at baseline and on study. Patients were assessed for recurrence and followed for DFS and overall survival. Grading of adverse events was performed using the Common Terminology Criteria of Adverse Events version 4. The objective of this report is to examine the pCR rate at the time of resection after one dose of pembrolizumab, and to evaluate pathologic response as a predictor of DFS. To date, 29 patients have received treatment on the trial and are included in this analysis.
Statistical analysis.
The primary objectives of the clinical trial are to establish safety and obtain paired tissue samples for analysis of immunologic effects. The target sample size was 30 patients. If 5 or fewer of 30 patients experienced a severe (grade 3 or higher) adverse event that was not attributable to pembrolizumab or to surgery alone, then safety was established since the true toxicity rate is probably no higher than 30% based on the upper bound of the 2-sided 95% confidence interval. A secondary objective of the trial was to study the biological changes in paired tumor tissue specimens before and in the presence of anti-PD-1. For this report, the primary end point was DFS from the date of definitive surgery to first documented disease recurrence, death due to any cause, or last patient contact documenting disease-free status. The rate of pathologic response (defined as complete or major pathologic response 5, 6 ) and exact 95% confidence interval were estimated for 29 patients who have enrolled and undergone surgery on the trial. Median potential follow-up was estimated by the reverse Kaplan-Meier method. DFS from landmark date of definitive surgery to first documented disease recurrence, death due to any cause, or last patient contact documenting disease-free status was estimated by the Kaplan-Meier method. Cox proportional hazards regression modeling was employed to estimate the magnitude of effect of pathologic response on DFS. Multivariable models were employed to adjust for established prognostic factors. Unadjusted and adjusted hazard ratios and their 95% confidence intervals were estimated. To address the low event rate in the group with pCR and the group with brisk TILs post-treatment, we applied Firth's penalized regression method for the Cox proportional hazard model, with the penalized likelihood ratio test 30 . For normal data, parametric Student's t-test and paired t-test were used for unpaired and paired analyses, respectively. For nonnormal data, non-parametric Mann-Whitney or Wilcoxon matched-pairs signed rank tests were used for unpaired and paired analyses, respectively. Correlations between continuous variables were determined by Pearson's r coefficient. Fisher's exact test was employed to test for association between two categorical variables. McNemar's test was used to test concordance between paired categorical variables to determine treatment effect (that is, pretreatment and post-treatment TIL score). Statistical analyses were performed using either IBM SPSS v23, R, or Graphpad Prism.
Sample processing: PBMCs and tumor. Patient blood was drawn in sodium heparin tubes, kept at room temperature, and processed within 8 h of blood draw. Whole blood was centrifuged and plasma samples were collected, aliquoted in the volume of 1 ml per cryotube, and stored at -80 °C. Blood samples were reconstituted by adding an equal volume of Hank's balanced salt solution (HBSS, Corning MT21021CM) to the volume of collected plasma. Reconstituted blood samples were diluted two-fold in HBSS and Ficoll (Ficoll-Paque PLUS density gradient medium, GE Healthcare Life Sciences, 17-1440-03) was layered underneath. The volume of Ficoll-Paque PLUS used was equal to that of the undiluted blood sample. The buffy coat was collected and washed twice with HBSS. Ammonium-chloride-potassium lysis buffer (Lonza 10-548E) was used to lyse the red blood cells, if necessary. Melanoma tumor samples were processed within 4 h after excision from the patient. Samples were cut into 2-3-mm pieces with a scalpel in an RPMI 1640 (Corning 10-040-CM)-containing petri dish. A 70-µm cell strainer (Falcon 352350) was placed on top of a 50-ml conical tube and the tissue fragments were transferred to the cell strainer with a pipette. The cells were released by gently grinding the tissue fragments using the thumb depressor of a sterile syringe plunger placed against the cell strainer. Cells were washed twice and counted in a hemocytometer. The numbers of lymphocytes and melanoma cells were distinguished by their morphology and recorded separately.
Flow cytometry. Fresh trial PBMCs and tumor suspension were stained with a master mix of antibodies for surface stains including CD4 (Biolegend, OKT4), CD8 (BD, RPA-T8), CD45RA (Biolegend, HI100), Tim-3 (Biolegend, F38-2E2), Lag3 (3DS223H, eBioscience), CD39 (Biolegend, A1), CD27 (BD, L128), and PD-1 (BD, EH12.1) and intracellular stains for FoxP3 (BD, 259D/C7), CTLA-4 (BD, BNI3), Eomes (eBioscience, WD1928), T-bet (Biolegend, 4B10), and Ki67 (BD, B56). HLA-A2 tetramers were generated at the National Institutes of Health tetramer facility for the melanoma gp100 peptide G280 (YLEPGPVTV) and CMV peptide pp65 (NLVPMVATV). Permeabilization was performed using the Foxp3 Fixation/ Permeabilization Concentrate and Diluent kit (eBioscience). PD-1 on postpembrolizumab specimens was detected using anti-human IgG4 phycoerythrin (Southern Biotec) as previously described 3, 31 . Cells were resuspended in 1% paraformaldehyde until acquisition on a BD Biosciences LSR II cytometer and analyzed using FlowJo (Tree Star).
Immunohistochemical staining and scoring of PD-L1 (single chromogenic).
Whole tissue sections cut from formalin-fixed paraffin-embedded (FFPE) tissue blocks were deparaffinized and rehydrated with serial passage through changes of xylene and graded ethanols. All slides were subjected to heat-induced epitope retrieval in Envision FLEX Target Retrieval Solution, High pH (Dako). Endogenous peroxidase in tissues was blocked by incubation of slides in 3% hydrogen peroxide solution before incubation with primary antibody (anti-PD-L1, clone 22C3, Merck Research Laboratories, or anti-PD-1 clone NAT105, Cell Marque) for 60 min. Antigen-antibody binding was visualized via application of the FLEX+ polymer system (Dako) via application of mouse Envision system, and application of 3, 3' diaminobenzidine chromogen (Dako). Stained slides were counterstained with hematoxylin and cover slipped for review. Scoring of PD-L1 was conducted by a pathologist blinded to patient characteristics and clinical outcomes 32 . A semiquantitative 0-5 scoring system was applied: negative, 0; rare, 1-individuated positive cells or only very small focus within or directly adjacent to tumor tissue; low, 2-infrequent small clusters of positive cells within or directly adjacent to tumor tissue; moderate, 3-single large cluster, multiple smaller clusters, or moderately dense diffuse infiltration, within or directly adjacent to tumor tissue; high, 4-single very large dense cluster, multiple large clusters, or dense diffuse infiltration; very high, 5-coalescing clusters, dense infiltration throughout the tumor tissue.
Immunofluorescent staining and image acquisition.
Multiplexed immunofluorescent staining was performed on a Dako autostainer (Agilent). The FFPE sections were rehydrated in a series of graded alcohols to distilled water. Antigen retrieval was performed in Target Retrieval Solution (TRS) citrate buffer (pH 6.0) using a pressure cooker. The slides were blocked in 1% casein blocking buffer for 30 min, followed by incubation with primary antibody for 1 h. Slides were incubated with polymer horseradish peroxidase-secondary antibody for 30 min followed by application of fluorophore-4 tyramide signal amplification dye (Opal 7 color kit, PerkinElmer). After detection of first primary antibody, the slides were stripped of any primary and secondary antibodies by treating the slides in AR6 (Perkin Elmer) antibody-stripping buffer in a microwave oven. Sequentially, the slides were stained with second or third primary antibody and the process was repeated. Nuclear staining was carried out with DAPI followed by cover slipping. CD8xFoxP3xCD163 triplex staining was accomplished with PerkinElmer Opal kit (PerkinElmer). CD8, FoxP3, and CD163, labeled with Opal fluorophores 690, 570, and 520, respectively, were sequentially applied to the tissue sections. CD8xCD3 duplex immunofluorescent staining was accomplished with Thermo Fisher Scientific Tyramide Signal Amplification kit (Thermo Scientific). The sequence for antibody staining is CD8 and CD3, labeled with Alexa fluorophores 488 and 568, respectively. Epifluorescence multispectral whole slide images of all sections were acquired through the Vectra 3.0 Automated Quantitative Pathology Imaging A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
Letters | FOCUS
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Data analysis R package 'limma_3.34.9' was used to do pairwise comparisons of the normalized Nanostring gene expression data. R package 'pheatmap_1.0.10' was used for creating heatmaps to display Nanostring gene expression data. Metascape.org was used to enrich genes for GO biological processes. Gene set enrichment analysis (GSEA)(PMID:17644558) using Broad Institute software (https:// software.broadinstitute.org/gsea/) was used to check for enrichment of gene signatures from microarray data in the Nanostring data. The GEP18 score was calculated as a weighted linear combination of 18 genes expression values for each sample. Statistical analyses were performed using either IBM SPSS v23 or Graphpad Prism v7. Flow cytometry analysis was performed using FlowJo v10
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Recruitment
This phase 1b clinical trial (NCT02434354), was a single institution investigator-initiated study sponsored by the University of Pennsylvania. The protocol and its amendments were approved by the Institutional Review Board at the University of Pennsylvania, and all patients provided written informed consent. Patients were eligible for enrolment if they were 18 years of age or older, had an Eastern Cooperative Group performance status of 0 or 1, adequate organ function according to protocol criteria, and had measurable resectable clinical stage III or resectable stage IV melanoma. Patients had to have an adequate tumor size, in the opinion of the surgical oncologist and study team, to allow for collection of biopsy tissue equivalent to at least two to four core biopsies for the pre-treatment biopsy, with an expectation that an equal or greater amount of tissue would remain after biopsy. Patients could not have received prior ipilimumab or other immune therapies. Prior BRAF directed therapies were permitted. Patients with uveal or mucosal melanoma were not eligible, nor were patients on systemic steroids or immunosuppression, patients who had received radiation to the resectable tumor, or patients with active brain metastasis. Patients seen at the University of Pennsylvania were recruited if they met eligibility criteria when seeing medical oncology or surgical oncology, including head and neck surgical oncology. Due to the fact that the primary sub-investigators were in surgical oncology, there may have been a bias leading to the inclusion of fewer patients with melanoma of the head and neck. However, the study did include patients with melanoma of the head and neck and we do not expect any impact on the study results.
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